• Ahmad F, Kannan M, Yadav V, Biswas A, Saxena R. Impact of thrombogenic mutations on clinical phenotypes of von Willebrand disease. Clin. Appl. Thromb. Hemost. Dec 2 [Epub ahead of print] (2009).

• Alcazar Navarrete B, Quiles Ruiz-Rico N, Gonzalez Vargas F, Cabrera Torres L. Bronchiectasis following colectomy in a patient with ulcerative colitis and factor V Leiden mutation. Arch. Bronconeumol. 41: 230-232 (2005). *

• Alessio AM, Hoehr NF, Siqueira LH, Ozelo MC, de Padua Mansur A, Annichino-Bizzacchi JM. Association between estrogen receptor alpha and beta gene polymorphisms and deep vein thrombosis. Thromb. Res. 120: 639-645 (2007). *

• Anstee QM, Wright M, Goldin R, Thursz MR. Parenchymal extinction: coagulation and hepatic fibrogenesis. Clin. Liver Dis. 13: 117-126 (2009).

• Arend SM, Leyten EM, Franken WP, Huisman EM, van Dissel JT. A patient with de novo tuberculosis during anti-tumor necrosis factor- alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin. Infect. Dis. 45: 1470-1475 (2007). *

• Attvall E, Frigyesi A, Sternby B. What is the impact of resistance to activated protein C (Leiden mutation to factor V) in inflammatory bowel disease? Int. J. Colorectal Dis. 21: 705-710 (2006). *

• Banait VS, Sandeep MS, Shetty S, Bapat MR, Rathi PM, Ghosh K, Mohanty D, Abraham P. Hypercoagulable state in idiopathic ulcerative colitis: role of hyperhomocysteinemia and hyperfibrinogenemia. Indian J. Gastroenterol. 27: 94-98 (2008). *

• Bayley JP, Bakker AM, Kaijzel EL, Huizinga TW, Verweij CL. Association of polymorphisms of the tumour necrosis factor receptors I and II and rheumatoid arthritis. Rheumatology (Oxford) 42: 969-971 (2003). *

• Benten D, Widjaja A, von Depka M, Flemming P, Trautwein C, Boker K, Vogel A, Rosenau J, Manns MP. Autoimmune hepatitis associated with coagulation disorders and immunethyreopathy. Z. Gastroenterol. 39: 837-840 (2001).

• Bernstein CN, Sargent M, Vos HL, Rosendaal FR. Mutations in clotting factors and inflammatory bowel disease. Am. J. Gastroenterol. 102: 338-343 (2007). *

• Bezemer ID, Arellano AR, Tong CH, Rowland CM, Ireland HA, Bauer KA, Catanese J, Reitsma PH, Doggen CJ, Devlin JJ, Rosendaal FR, Bare LA. F9 Malmo, factor IX and deep vein thrombosis. Haematologica 94: 693-699 (2009). *

• Bjerregaard LT, Nederby NJ, Fredholm L, Brandslund I, Munkholm P, Hey H. Hyperhomocysteinaemia, coagulation pathway activation and thrombophilia in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 37: 62-67 (2002). *

• Bladt V, Steengaard-Pedersen K, Poulsen LH, Petersen OB, Laursen B, d'Amore F. Late puerperal thrombohemorrhagic complications in a patient with antiphospholipid syndrome. Eur. J. Haematol. 73: 437-440 (2004). *

• Botha-Scheepers SA, Watt I, Slagboom E, de Craen AJ, Meulenbelt I, Rosendaal FR, Breedveld FC, Huizinga TW, Kloppenburg M. Innate production of tumor necrosis factor-alpha and interleukin-10 is associated with radiological progression of knee osteoarthritis. Ann. Rheum. Dis. 67: 1165-1169 (2008).

• Bouaziz-Borgi L, Nguyen P, Hezard N, Musharrafieh U, Almawi WY, Mahjoub T. A case control study of deep venous thrombosis in relation to factor V G1691A (Leiden) and A4070G (HR2 haplotype) polymorphisms. Exp. Mol. Pathol. 83: 480-483 (2007).

• Brancaccio V, Iannaccone L, Margaglione M, Guardascione MA, Amitrano L. Multiple thrombophilic factors in a patient with Budd-Chiari syndrome. Clin. Lab. Haematol. 24: 61-63 (2002). *

• Breedveld FC. Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept. Ned. Tijdschr. Geneeskd. 149: 2273-2277 (2005).

• Casella G, Perego D, Baldini V, Monti C, Crippa S, Buda CA. A rare association between ulcerative colitis (UC), celiac disease (CD), membranous glomerulonephritis, leg venous thrombosis, and heterozygosity for factor V Leiden. J. Gastroenterol. 37: 761-762 (2002). *

• Ceelie H, Spaargaren-Van Riel CC, De Jong M, Bertina RM, Vos HL. Functional characterization of transcription factor binding sites for HNF1-alpha, HNF3-beta (FOXA2), HNF4-alpha, Sp1 and Sp3 in the human prothrombin gene enhancer. J. Thromb. Haemost. 1: 1688-1698 (2003). *

• Ciacci C, Tortora R, Scudiero O, Di Fiore R, Salvatore F, Castaldo G. Early pregnancy loss in celiac women: the role of genetic markers of thrombophilia. Dig. Liver Dis. 41: 717-720 (2009).

• Cochery-Nouvellon E, Vitry F, Cornillet-Lefebvre P, Hezard N, Gillot L, Nguyen P. Interleukin-10 promoter polymorphism and venous thrombosis: a case-control study. Thromb. Haemost. 96: 24-28 (2006).

• Cupedo T, Crellin NK, Papazian N, Rombouts EJ, Weijer K, Grogan JL, Fibbe WE, Cornelissen JJ, Spits H. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC(+) CD127(+) natural killer-like cells. Nat. Immunol. 10: 66-74 (2009). *

• Dagan E, Brik R, Broza Y, Gershoni-Baruch R. Henoch-Schonlein purpura: polymorphisms in thrombophilia genes. Pediatr. Nephrol. 21: 1117-1121 (2006). *

• de Jong BA, Westendorp RG, Bakker AM, Huizinga TW. Polymorphisms in or near tumour necrosis factor (TNF)-gene do not determine levels of endotoxin-induced TNF production. Genes Immun. 3: 25-29 (2002). *

• de Paula Sabino A, Ribeiro DD, Carvalho MD, Cardoso J, Dusse LM, Fernandes AP. Factor V Leiden and increased risk for arterial thrombotic disease in young Brazilian patients. Blood Coagul. Fibrinolysis 17: 271-275 (2006).

• Delarive J, Gonvers JJ. Budd-Chiari syndrome related to factor V Leiden mutation. Am. J. Gastroenterol. 93: 651-652 (1998). *

• Deltenre P, Denninger MH, Hillaire S, Guillin MC, Casadevall N, Briere J, Erlinger S, Valla DC. Factor V Leiden related Budd-Chiari syndrome. Gut 48: 264-268 (2001). *

• Dunn SP, Tsai A, Griffin G, Toth S, Casas-Melley AT, Falkenstein KP, Marando CA, Krueger LJ. Liver transplantation as definitive treatment for a factor V Leiden mutation. J. Pediatr. 146: 418-422 (2005). *

• Eroglu A, Egin Y, Cam R, Akar N. The 19-bp deletion of dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR) C677T, factor V Leiden, prothrombin G20210A polymorphisms in cancer patients with and without thrombosis. Ann. Hematol. 88: 73-76 (2009). *

• Eroglu A, Sertkaya-Karasoy D, Eroglu N, Akar N. Factor V 1691 G-A (Leiden) polymorphism and cancer-related venous thromboembolism: a meta-analysis of published studies. J. BUON 13: 61-64 (2008).

• Eroglu A, Ulu A, Cam R, Kurtman C, Akar N. Prevalence of factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients. J. Thromb. Thrombolysis 23: 31-34 (2007). *

• Esther van de Vosse, Ottenhoff TH. Human host genetic factors in mycobacterial and Salmonella infection: lessons from single gene disorders in IL-12/IL-23-dependent signaling that affect innate and adaptive immunity. Microbes Infect. 8: 1167-1173 (2006). *

• Famularo G, Minisola G, Nicotra GC, Simone CD. Mesenteric and portal vein thrombosis associated with hyperhomocysteinemia and heterozygosity for factor V Leiden mutation. World J. Gastroenterol. 11: 7700-7701 (2005). *

• Favaloro EJ. Diagnostic issues in thrombophilia: a laboratory scientist's view. Semin. Thromb. Hemost. 31: 11-16 (2005).

• Favaloro EJ. Learning from peer assessment: the role of the external quality assurance multilaboratory thrombophilia test process. Semin. Thromb. Hemost. 31: 85-89 (2005).

• Favaloro EJ, Bonar R, Sioufi J, Wheeler M, Low J, Aboud M, Duncan E, Smith J, Exner T, Lloyd J, Marsden K. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology. Semin. Thromb. Hemost. 31: 49-58 (2005).

• Gao Q, Hogezand RA, Lamers CB, Verspaget HW. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease. Aliment. Pharmacol. Ther. 20: 585-592 (2004). *

• Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, Rimmelzwaan GF, Kroon FP. The effect of anti-tumor necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann. Rheum. Dis. 67: 713-716 (2008).

• Girard G, Bloemberg GV. Central role of quorum sensing in regulating the production of pathogenicity factors in Pseudomonas aeruginosa. Future Microbiol. 3: 97-106 (2008).

• Glueck CJ, Freiberg RA, Boppana S, Wang P. Thrombophilia, hypofibrinolysis, the eNOS T-786C polymorphism, and multifocal osteonecrosis. J. Bone Joint Surg. Am. 90: 2220-2229 (2008).

• Glueck CJ, Pranikoff J, Aregawi D, Haque M, Zhu B, Tracy T, Wang P. The factor V Leiden mutation, high factor VIII, and high plasminogen activator inhibitor activity: etiologies for sporadic miscarriage. Metabolism 54: 1345-1349 (2005).

• Hahn T, McCarthy PL Jr, Zhang MJ, Wang D, Arora M, Frangoul H, Gale RP, Hale GA, Horan J, Isola L, Maziarz RT, van Rood JJ, Gupta V, Halter J, Reddy V, Tiberghien P, Litzow M, Anasetti C, Pavletic S, Ringden O. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J. Clin. Oncol. 26: 5728-5734 (2008).

• Haslam N, Standen GR, Probert CS. An investigation of the association of the prothrombin G20210A gene mutation and inflammatory bowel disease: factor II and IBD. Inflamm. Bowel Dis. 7: 133-135 (2001). *

• Haslam N, Standen GR, Probert CS. An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 11: 1289-1291 (1999).

• Heijmans BT, Westendorp RG, Droog S, Kluft C, Knook DL, Slagboom PE. Association of the tumour necrosis factor alpha -308G/A polymorphism with the risk of diabetes in an elderly population-based cohort. Genes Immun. 3: 225-228 (2002). *

• Helio T, Wartiovaara U, Halme L, Turunen UM, Mikkola H, Palotie A, Farkkila M, Kontula K. Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease. Scand. J. Gastroenterol. 34: 170-174 (1999). *

• Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch. Intern. Med. 166: 729-736 (2006). *

• Hoffman R, Nimer A, Lanir N, Brenner B, Baruch Y. Budd-Chiari syndrome associated with factor V leiden mutation: a report of 6 patients. Liver Transpl. Surg. 5: 96-100 (1999).

• Hotoleanu C, Porojan-Iuga M, Rusu ML, Andercou A. Hyperhomocysteinemia: clinical and therapeutical involvement in venous thrombosis. Rom. J. Intern. Med. 45: 159-164 (2007).

• Hron G, Eichinger S, Weltermann A, Minar E, Bialonczyk C, Hirschl M, Stain M, Gartner V, Kyrle PA. Family history for venous thromboembolism and the risk for recurrence. Am. J. Med. 119: 50-53 (2006). *

• Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA, Jawaheer D, Schreuder GM, Wener M, Breedveld FC, Ahmad N, Lum RF, de Vries RR, Gregersen PK, Toes RE, Criswell LA. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 52: 3433-3438 (2005). *

• Ivanov P, Komsa-Penkova R, Kovacheva K, Ivanov Y, Stoyanova A, Ivanov I, Pavlov P, Glogovska P, Nojarov V. Impact of thrombophilic genetic factors on pulmonary embolism: early onset and recurrent incidences. Lung 186: 27-36 (2008).

• Jackson LM, O'Gorman PJ, O'Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM 90: 183-188 (1997). *

• Jilma B, Kovar FM, Hron G, Endler G, Marsik CL, Eichinger S, Kyrle PA. Homozygosity in the single nucleotide polymorphism Ser128Arg in the E-selectin gene associated with recurrent venous thromboembolism. Arch. Intern. Med. 166: 1655-1659 (2006). *

• Jonkers IJ, Smelt AH, Ledeboer M, Hollum ME, Biemond I, Kuipers F, Stellaard F, Boverhof R, Meinders AE, Lamers CH, Masclee AA. Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil. Gut 52: 109-115 (2003). *

• Kader HA, Berman WF, Al-Seraihy AS, Ware RE, Ulshen MH, Treem WR. Prevalence of factor V G1691A (Leiden), prothrombin G20210A, and methylene tetrahydrofolate reductase C677T thrombophilic mutations in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 35: 629-635 (2002). *

• Kaijzel EL, Bayley JP, van Krugten MV, Smith L, van de Linde P, Bakker AM, Breedveld FC, Huizinga TW, Verweij CL. Allele-specific quantification of tumor necrosis factor alpha (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes Immun. 2: 135-144 (2001). *

• Kaijzel EL, Brinkman BM, van Krugten MV, Smith L, Huizinga TW, Verjans GM, Breedveld FC, Verweij CL. Polymorphism within the tumor necrosis factor alpha (TNF) promoter region in patients with ankylosing spondylitis. Hum. Immunol. 60: 140-144 (1999).

• Kaiser R, Barton JL, Chang M, Catanese JJ, Li Y, Begovich AB, Criswell LA. Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a meta-analysis. Genes Immun. 10: 495-502 (2009).

• Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der Helm-van Mil AH, Toes RE, Huizinga TW, Klareskog L, Alfredsson L; Epidemiological Investigation of Rheumatoid Arthritis (EIRA) Study Group. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am. J. Hum. Genet. 80: 867-875 (2007). *

• Khenifer S, Thomas L, Balme B, Dalle S. Livedoid vasculiltis associated with a double heterozygous factor V Leiden and prothrombin G20210A gene mutations. Clin. Exp. Dermatol. Sep 28 [Epub ahead of print] (2009). *

• Komitopoulou A, Platokouki H, Kapsimali Z, Moschovi M, Kattamis A, Pergantou H, Aronis S. Mutations and polymorphisms in genes affecting haemostasis components in children with thromboembolic events. Pathophysiol. Haemost. Thromb. 35: 392-397 (2006).

• Koutroubakis IE. Therapy insight: vascular complications in patients with inflammatory bowel disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 266-272 (2005). *

• Koutroubakis IE, Sfiridaki A, Mouzas IA, Maladaki A, Kapsoritakis A, Roussomoustakaki M, Kouroumalis EA, Manousos ON. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. Am. J. Gastroenterol. 95: 190-194 (2000). *

• Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Theodoropoulou A, Livadiotaki A, Paspatis G, Kouroumalis EA. Genetic risk factors in patients with inflammatory bowel disease and vascular complications: case-control study. Inflamm. Bowel Dis. 13: 410-415 (2007). *

• Kruse L, Mitchell AM, Camargo CA Jr, Hernandez J, Kline JA. Frequency of thrombophilia-related genetic variations in patients with idiopathic pulmonary embolism in an urban emergency department. Clin. Chem. 52: 1026-1032 (2006). *

• Kurreeman FA, Rocha D, Houwing-Duistermaat J, Vrijmoet S, Teixeira VH, Migliorini P, Balsa A, Westhovens R, Barrera P, Alves H, Vaz C, Fernandes M, Pascual-Salcedo D, Michou L, Bombardieri S, Radstake T, van Riel P, van de Putte L, Lopes-Vaz A, et al. Replication of the tumor necrosis factor receptor-associated factor 1/complement component 5 region as a susceptibility locus for rheumatoid arthritis in a European family-based study. Arthritis Rheum. 58: 2670-2674 (2008). *

• Liew M, Pryor R, Palais R, Meadows C, Erali M, Lyon E, Wittwer C. Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clin. Chem. 50: 1156-1164 (2004). *

• Lincz LF, Adams MJ, Scorgie FE, Thom J, Baker RI, Seldon M. Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden. Blood Coagul. Fibrinolysis 18: 559-564 (2007).

• Linn-Rasker SP, van der Helm-van Mil AH, Van Gaalen FA, Kloppenburg M, de Vries R, le Cessie S, Breedveld FC, Toes RE, Huizinga TW. Smoking is a risk factor for anti-CCP antibodies only in RA patients that carry HLA-DRB1 shared epitope alleles. Ann. Rheum. Dis. 65: 366-371 (2006). *

• Lobrano A, Blanchard K, Rock W, Johnson W, Schmieg B, Borman K, Araghizadeh F, Minocha A, Abell TL. Assessing thrombosis risk in patients with idiopathic, diabetic, and postsurgical gastroparesis. Adv. Ther. 23: 750-768 (2006).

• Lunghi B, Scanavini D, Castoldi E, Gemmati D, Tognazzo S, Redaelli R, Ghirarduzzi A, Ieran M, Pinotti M, Bernardi F. The factor V Glu1608Lys mutation is recurrent in familial thrombophilia. J. Thromb. Haemost. 3: 2032-2038 (2005). *

• Maher MM, Soloma SH. Assessment of thrombophilic abnormalities during the active state of inflammatory bowel disease. Saudi J. Gastroenterol. 14: 192-197 (2008). *

• Mahmood A, Needham J, Prosser J, Mainwaring J, Trebble T, Mahy G, Ramage J. Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 17: 739-744 (2005).

• Mari T, Zullo A, Hassan C, Di Giulio L, Morini S. Genetic association between factor V Leiden and coeliac disease. Gut 55: 1677-1678 (2006). *

• Martinelli I, Battaglioli T, Tosetto A, Legnani C, Sottile L, Ghiotto R, Mannucci P. Prothrombin 19911 A>G polymorphism and the risk of venous thromboembolism. J. Thromb. Haemost. 4: 2582-2586 (2006). *

• Mazoyer E, Ripoll L, Gueguen R, Tiret L, Collet JP, Sollier CB, Roussi J, Drouet L; for the FITENAT Study Group. Prevalence of factor V Leiden and prothrombin G20210A mutation in a large French population selected for nonthrombotic history: geographical and age distribution. Blood Coagul. Fibrinolysis Aug 27 [Epub ahead of print] (2009).

• Meesters EW, Hansen H, Spronk HM, Hamulyak K, Rosing J, Rowshani AT, Ten Berge IJ, Ten Cate H. The inflammation and coagulation cross-talk in patients with systemic lupus erythematosus. Blood Coagul. Fibrinolysis 18: 21-28 (2007).

• Meijer MJ, Mieremet-Ooms MA, van Duijn W, van der Zon AM, Hanemaaijer R, Verheijen JH, van Hogezand RA, Lamers CB, Verspaget HW. Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm. Bowel Dis. 13: 200-210 (2007). *

• Meijer MJ, Mieremet-Ooms MA, van Hogezand RA, Lamers CB, Hommes DW, Verspaget HW. Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J. Gastroenterol. 13: 2960-2966 (2007). *

• Mikula M, Buller A, Sun W, Strom CM. Prevalence of known mutations in the familial Mediterranean fever gene (MEFV) in various carrier screening populations. Genet. Med. 10: 349-352 (2008).

• Mouelhi L, Mekki H, Debbeche R, Salem M, Najjar T. Thrombosis in inflammatory bowel disease: mechanisms and risk factors. Tunis. Med. 87: 307-310 (2009).

• Mozafari H, Rahimi Z, Heidarpour A, Fallahi M, Muniz A. The prevalence of factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate reductase polymorphism C677T among G6PD deficient individuals from Western Iran. Mol. Biol. Rep. 36: 2361-2364 (2009). *

• Mozsik G, Nagy Z, Nagy A, Rumi G, Karadi O, Czimmer J, Matus Z, Toth G, Par A. Leiden mutation (as genetic) and environmental (retinoids) sequences in the acute and chronic inflammatory and premalignant colon disease in human gastrointestinal tract. J. Physiol. Paris 95: 489-494 (2001).

• Muetze S, Leeners B, Ortlepp JR, Kuse S, Tag CG, Weiskirchen R, Gressner AM, Rudnik-Schoeneborn S, Zerres K, Rath W. Maternal factor V Leiden mutation is associated with HELLP syndrome in Caucasian women. Acta Obstet. Gynecol. Scand. 87: 635-642 (2008).

• Nagy Z, Nagy A, Karadi O, Figler M, Rumi G Jr, Suto G, Vincze A, Par A, Mozsik G. Prevalence of the factor V Leiden mutation in human inflammatory bowel disease with different activity. J. Physiol. Paris 95: 483-487 (2001).

• Nagy Z, Nagy A, Karadi O, Figler M, Suto G, Vincze A, Par A, Mozsik G. Leiden mutation in patients with Crohn's disease. Inflammopharmacology 7: 297-301 (1999).

• Nagy Z, Nagy A, Karadi O, Par A, Mozsik G. The high prevalence of the factor V Leiden mutation in central European inflammatory bowel disease patients. Am. J. Gastroenterol. 95: 3013-3014 (2000). *

• Naushad S, Jamal MN, Angalena R, Prasad CK, Devi AR. Hyperhomocysteinemia and the compound heterozygous state for methylene tetrahydrofolate reductase are independent risk factors for deep vein thrombosis among South Indians. Blood Coagul. Fibrinolysis 18: 113-117 (2007).

• Nurk E, Tell GS, Refsum H, Ueland PM, Vollset SE. Factor V Leiden, pregnancy complications and adverse outcomes: the Hordaland Homocysteine Study. QJM 99: 289-298 (2006). *

• Oguzulgen IK, Demirtas S, Erkekol FO, Ekim N, Demir N, Numanoglu N, Ozel D, Ulu A, Akar N. The role of plasminogen activator inhibitor-1 polymorphism, factor-V-leiden, and prothrombin-20210 mutations in pulmonary thromboembolism. Clin. Appl. Thromb. Hemost. 15: 73-77 (2009).

• Oldenburg B, Van Tuyl BA, van der Griend R, Fijnheer R, van Berge Henegouwen GP. Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. Dig. Dis. Sci. 50: 235-240 (2005). *

• Otrock ZK, Taher AT, Shamseddeen WA, Zaatari G, Bazarbachi A, Mahfouz RA. Factor V HR2 haplotype: a risk factor for venous thromboembolism in individuals with absence of factor V Leiden. Ann. Hematol. 87: 1013-1016 (2008). *

• Over HH, Ulgen S, Tuglular T, Tezel A, Avsar E, Geyik G, Basgul S, Sayhan N, Ulusoy N, Kalayci C, Tozun N. Thrombophilia and inflammatory bowel disease: does factor V mutation have a role? Eur. J. Gastroenterol. Hepatol. 10: 827-829 (1998).

• Over-Hamzaoglu H, Abaci N, Ture F, Alkim C, Tezel A, Avsar E, Tozun N. Prothrombotic gene mutations and Crohn's disease; is there any association? Hepatogastroenterology 52: 1467-1469 (2005).

• Papa A, De Stefano V, Gasbarrini A, Chiusolo P, Cianci R, Casorelli I, Paciaroni K, Cammarota G, Leone G, Gasbarrini G. Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. Blood Coagul. Fibrinolysis 11: 499-503 (2000).

• Payzin B, Adakan FY, Yalcin HC, Cetinkaya GS, Berkmen S, Eraslan S, Unsal B. Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease. Turk. J. Gastroenterol. 17: 183-190 (2006). *

• Primignani M, Martinelli I, Bucciarelli P, Battaglioli T, Reati R, Fabris F, Dell'era A, Pappalardo E, Mannucci PM. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 41: 603-608 (2005). *

• Procare-GEHT Group*; Biron-Andreani C, Morange P. ABO blood group but not haemostasis genetic polymorphisms significantly influence thrombotic risk: a study of 180 homozygotes for the factor V Leiden mutation. Br. J. Haematol. 135: 697-702 (2006). *

• Rahimi Z, Ghaderi M, Nagel RL, Muniz A. Prevalence of thrombotic risk factors among beta-thalassemia patients from Western Iran. J. Thromb. Thrombolysis 26: 229-233 (2008).

• Rahimi Z, Nomani H, Mozafari H, Vaisi-Raygani A, Madani H, Malek-Khosravi S, Parsian A. Factor V G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase polymorphism C677T are not associated with coronary artery disease and type 2 diabetes mellitus in Western Iran. Blood Coagul. Fibrinolysis 20: 252-256 (2009).

• Rajewski M, Skrzypczak J. Frequency of antiphospholipid antibodies and factor V (G1691A), prothrombin (G20210A) gene polimorphism among women with pregnancy complications. Pol. Arch. Med. Wewn. 115: 417-425 (2006).

• Ricketts ML, Boekschoten MV, Kreeft AJ, Hooiveld GJ, Moen CJ, Muller M, Frants RR, Kasanmoentalib S, Post SM, Princen HM, Porter JG, Katan MB, Hofker MH, Moore DD. The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors. Mol. Endocrinol. 21: 1603-1616 (2007). *

• Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 95: 1777-1782 (1997). *

• Robison NJ, Dawlabani N, Lastra CR, Dhall G. Cerebral sinus thrombosis in a child with active ulcerative colitis and factor V Leiden. Pediatr. Blood Cancer 52: 867-869 (2009).

• Rubio-Jurado B, Salazar-Paramo M, Medrano-Munoz F, Gonzalez-Ojeda A, Nava A. Thrombophilia, autoimmunity, and perioperative thromboprophylaxis. Cir. Cir. 75: 313-321 (2007).

• Ruh J, Malago M, Busch Y, Lang H, Paul A, Verhagen R, Broelsch CE. Management of Budd-Chiari syndrome. Dig. Dis. Sci. 50: 540-546 (2005). *

• Senzolo M, Burra P, Cholongitas E, Burroughs AK. New insights into the coagulopathy of liver disease and liver transplantation. World J. Gastroenterol. 12: 7725-7736 (2006). *

• Seremak-Mrozikiewicz A, Drews K, Wender-Ozegowska E, Mrozikiewicz PM. The significance of genetic polymorphisms of factor V Leiden and prothrombin in the preeclamptic Polish women. J. Thromb. Thrombolysis Dec 29 [Epub ahead of print] (2009).

• Sharma S, Kumar SI, Poddar U, Yachha SK, Aggarwal R. Factor V Leiden and prothrombin gene G20210A mutations are uncommon in portal vein thrombosis in India. Indian J. Gastroenterol. 25: 236-239 (2006). *

• Simchen MJ, Goldstein G, Lubetsky A, Strauss T, Schiff E, Kenet G. Factor V Leiden and antiphospholipid antibodies in either mothers or infants increase the risk for perinatal arterial ischemic stroke. Stroke 40: 65-70 (2009).

• Spek CA, Ten Kate FJ, Te Velde AA. Factor V Leiden and the etiology of inflammatory bowel disease. Thromb. Haemost. 98: 670-673 (2007).

• Spina L, Saibeni S, Battaglioli T, Peyvandi F, de Franchis R, Vecchi M. Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am. J. Gastroenterol. 100: 2036-2041 (2005). *

• Srirajaskanthan R, Winter M, Muller AF. Venous thrombosis in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 17: 697-700 (2005).

• Staropoli JF, Van Cott EM, Makar RS. Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance. Transfusion 48: 2435-2441 (2008).

• Theodoropoulou A, Sfiridaki A, Oustamanolakis P, Vardas E, Livadiotaki A, Boumpaki A, Paspatis G, Koutroubakis IE. Genetic risk factors in young patients with ischemic colitis. Clin. Gastroenterol. Hepatol. 6: 907-911 (2008).

• Toruner M, Erkan O, Soykan I, Bozdayi M, Cetinkaya H, Yurdaydin C, Uzunalimoglu O, Ozden A. Factor V Leiden, prothrombin G20210A and MTHFR gene mutations in inflammatory bowel disease. Turk. J. Gastroenterol. 15: 250-252 (2004). *

• Trompet S, de Craen AJ, Slagboom P, Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Ford I, Gaw A, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Jukema JW; on behalf of the PROSPER Group. Lymphotoxin-alpha C804A polymorphism is a risk factor for stroke. The PROSPER study. Exp. Gerontol. 43: 801-805 (2008).

• Tsiolakidou G, Koutroubakis IE. Thrombosis and inflammatory bowel disease-the role of genetic risk factors. World J. Gastroenterol. 14: 4440-4444 (2008). *

• Tukiainen E, Kylanpaa ML, Repo H, Orpana A, Methuen T, Salaspuro M, Kemppainen E, Puolakkainen P. Hemostatic gene polymorphisms in severe acute pancreatitis. Pancreas 38: e43-e46 (2009).

• Turri D, Rosselli M, Simioni P, Tormene D, Grimaudo S, Martorana G, Siragusa S, Mariani G, Cottone M, Siracusa S. Factor V Leiden and prothrombin gene mutation in inflammatory bowel disease in a Mediterranean area. Dig. Liver Dis. 33: 559-562 (2001).

• Van Bezooijen RL, Van Der Wee-Pals L, Papapoulos SE, Lowik CW. Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann. Rheum. Dis. 61: 870-876 (2002). *

• Van Der Helm-Van Mil AH, Dieude P, Schonkeren JJ, Cornelis F, Huizinga TW. No association between tumour necrosis factor receptor type 2 gene polymorphism and rheumatoid arthritis severity: a comparison of the extremes of phenotypes. Rheumatology (Oxford) 43: 1232-1234 (2004). *

• van der Helm-van Mil AH, Huizinga TW, de Vries RR, Toes RE. Emerging patterns of risk factor make-up enable subclassification of rheumatoid arthritis. Arthritis Rheum. 56: 1728-1735 (2007). *

• van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum. 54: 1117-1121 (2006). *

• van der Helm-van Mil AH, Verpoort KN, le Cessie S, Huizinga TW, de Vries RR, Toes RE. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum. 56: 425-432 (2007). *

• van der Linden MP, Feitsma AL, le Cessie S, Kern M, Olsson LM, Raychaudhuri S, Begovich AB, Chang M, Catanese JJ, Kurreeman FA, van Nies J, van der Heijde DM, Gregersen PK, Huizinga TW, Toes RE, van der Helm-Van Mil AH. Association of a single-nucleotide polymorphism in CD40 with the rate of joint destruction in rheumatoid arthritis. Arthritis Rheum. 60: 2242-2247 (2009). *

• van der Veek PP, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-a and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am. J. Gastroenterol. 100: 2510-2516 (2005). *

• van der Woude D, Huizinga TW. The battle between anti-cyclic citrullinated peptide and rheumatoid factor tests - a winner at last? Nat. Clin. Pract. Rheumatol. 3: 696-697 (2007). *

• van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, Huizinga TW, van der Helm-van Mil AH. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 60: 2262-2271 (2009). *

• van Gaalen FA. Testing for antibodies to cyclic citrullinated peptides and rheumatoid factor - what is best for early RA? Nat. Clin. Pract. Rheumatol. 3: 488-489 (2007). *

• van Hogezand RA, Banffer D, Zwinderman AH, McCloskey EV, Griffioen G, Hamdy NA. Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease. Osteoporos. Int. 17: 535-542 (2006).

• van Hogezand RA, Verspaget HW. The future role of anti-tumour necrosis factor-alpha products in the treatment of Crohn's disease. Drugs 56: 299-305 (1998).

• Varga EA. Genetics in the context of thrombophilia. J. Thromb. Thrombolysis 25: 2-5 (2008).

• Vecchi M, Sacchi E, Saibeni S, Meucci G, Tagliabue L, Duca F, De Franchis R. Inflammatory bowel diseases are not associated with major hereditary conditions predisposing to thrombosis. Dig. Dis. Sci. 45: 1465-1469 (2000). *

• Verpoort KN, Papendrecht-van der Voort EA, van der Helm-van Mil AH, Jol-van der Zijde CM, van Tol MJ, Drijfhout JW, Breedveld FC, de Vries RR, Huizinga TW, Toes RE. Association of smoking with the constitution of the anti-cyclic citrullinated peptide response in the absence of HLA-DRB1 shared epitope alleles. Arthritis Rheum. 56: 2913-2918 (2007). *

• Verpoort KN, van Gaalen FA, van der Helm-van Mil AH, Schreuder GM, Breedveld FC, Huizinga TW, de Vries RR, Toes RE. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum. 52: 3058-3062 (2005). *

• Visser H, Vos K, Zanelli E, Verduyn W, Schreuder GM, Speyer I, Breedveld FC, Hazes JM. Sarcoid arthritis: clinical characteristics, diagnostic aspects, and risk factors. Ann. Rheum. Dis. 61: 499-504 (2002). *

• Wesoly J, Hu X, Thabet MM, Chang M, Uh H, Allaart CF, Toes RE, Houwing-Duistermaat JJ, Begovich AB, Huizinga TW. The 620W allele is the PTPN22 genetic variant conferring susceptibility to RA in a Dutch population. Rheumatology (Oxford) 46: 617-621 (2007). *

• Willeke P, Domagk D, Floer M, Bruwer M, Kreuter M, Gaubitz M, Domschke W, Kucharzik T. Ischaemic colitis mimicking inflammatory bowel disease in a young adult receiving oral anticoagulation. Scand. J. Gastroenterol. 40: 878-880 (2005). *

• Winn-Deen ES. Standards and controls for genetic testing. Cancer Biomark. 1: 217-220 (2005).

• Yakaryilmaz F, Guliter S, Degertekin B, Tuncer C, Unal S. Cerebral sinus thrombosis in a patient with active ulcerative colitis and double heterozygosity for factor V Leiden and prothrombin gene mutations. Neurol. India 57: 188-90 (2009). *

• Yasa MH, Bolaman Z, Yukselen V, Kadikoylu G, Karaoglul AO, Batun S. Factor V Leiden G1691A, prothrombin G20210A, and MTHFR C677T mutations in Turkish inflammatory bowel disease patients. Hepatogastroenterology 54: 1438-1442 (2007).

• Zauber NP, Sabbath-Solitare M, Rajoria G, Mogan G. Factor V Leiden mutation is not increased in patients with inflammatory bowel disease. J. Clin. Gastroenterol. 27: 215-216 (1998).

• Zee RY, Glynn RJ, Cheng S, Steiner L, Rose L, Ridker PM. An evaluation of candidate genes of inflammation and thrombosis in relation to the risk of venous thromboembolism: the Women's Genome Health Study. Circ. Cardiovasc. Genet. 2: 57-62 (2009).

• Zezos P, Papaioannou G, Nikolaidis N, Vasiliadis T, Giouleme O, Evgenidis N. Thrombophilic abnormalities of natural anticoagulants in patients with ulcerative colitis. Hepatogastroenterology 54: 1417-1421 (2007).

Number of references = 146

www psc-literature.org